fidaxomicin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile-associated Diarrhea
Conditions
Clostridium Difficile-associated Diarrhea
Trial Timeline
Jun 15, 2012 → Mar 7, 2014
NCT ID
NCT01591863About fidaxomicin
fidaxomicin is a phase 2 stage product being developed by Merck for Clostridium Difficile-associated Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT01591863. Target conditions include Clostridium Difficile-associated Diarrhea.
What happened to similar drugs?
9 of 20 similar drugs in Clostridium Difficile-associated Diarrhea were approved
Approved (9) Terminated (5) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04070352 | Pre-clinical | Withdrawn |
| NCT01591863 | Phase 2 | Completed |
Competing Products
20 competing products in Clostridium Difficile-associated Diarrhea